AI-based cfDNA fragmentome liquid biopsy can detect early liver fibrosis, cirrhosis, and indicate broader chronic disease signals.
Key Details
- 1Johns Hopkins team applied AI and genome-wide cfDNA fragmentation analysis to diagnose early liver fibrosis and cirrhosis.
- 2Study analyzed samples from 1,576 people with liver disease and comorbidities using whole-genome sequencing.
- 3AI algorithms identified disease-specific fragmentation patterns, enabling high sensitivity detection of early liver disease.
- 4Current clinical tests often miss early fibrosis and only detect cirrhosis around 50% of the time.
- 5Prototype assay also signaled risk for other chronic diseases, such as cardiovascular and inflammatory conditions.
- 6Technology builds upon earlier cancer fragmentome studies, focusing now on non-cancer chronic conditions.
Why It Matters
Early detection of liver fibrosis is critical because it is reversible at early stages, potentially preventing progression to cirrhosis and cancer. This AI-enabled cfDNA approach could expand the role of noninvasive liquid biopsy in radiological diagnostics and broader chronic disease management.
Source
EurekAlert
Related News
•EurekAlert
New Framework Compares AI Segmentation Without Ground Truth Annotations
Researchers introduce an open-source approach for evaluating AI anatomy segmentation models in medical imaging without requiring ground truth annotations.
•EurekAlert
AI-Driven Handheld Endomicroscope Enhances Early Cancer Detection
Researchers develop PrecisionView, a handheld AI-powered endomicroscope for real-time, high-resolution cancer diagnostics.
•EurekAlert
FDA Approves Johns Hopkins AI Tool for Early Sepsis Detection
FDA clears an AI-driven system developed by Johns Hopkins to detect sepsis up to 48 hours earlier and reduce mortality rates.